# To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects

> **NCT06705998** · PHASE1 · RECRUITING · sponsor: **BAR Pharmaceuticals s.r.l.** · enrollment: 52 (estimated)

## Conditions studied

- NASH

## Interventions

- **DRUG:** BAR502 single dose
- **DRUG:** Placebo single dose
- **DRUG:** BAR502 multiple doses

## Key facts

- **NCT ID:** NCT06705998
- **Lead sponsor:** BAR Pharmaceuticals s.r.l.
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-07-30
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705998, "To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06705998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*